The Latest
-
FDA warns Beta Bionics on unreported complaints, insulin pump changes
The Food and Drug Administration warning letter detailed unreported low blood sugar and a software change to correct for delayed glucose readings.
-
Medtech M&A starts off strong in 2026
Boston Scientific's planned $14.5 billion acquisition of Penumbra is the largest deal of the year so far.
-
Quantum Surgical buys J&J’s NeuWave
Quantum, developer of the Epione robotic platform for cancer treatment, said the acquisition supports its strategy of reducing cancer mortality through robot-assisted tumor ablation.
-
FDA posts early alert for safety issue with Impella heart pump devices
The cassettes have an increased risk of purge leaks that can lead to the loss of hemodynamic support.
-
Labcorp expands PathAI pact to roll out digital pathology platform in US
Labcorp’s pathologists will use the software to review, interpret and manage digital images of slides for primary diagnosis.
-
Medtronic’s MiniMed prices IPO at up to $784M
The diabetes spinoff plans to offer 28 million shares at $25 to $28 each.
-
AdvaMed names Jake Leach as chair of diabetes sector
The Dexcom CEO will lead the lobbying group’s sector representing diabetes tech companies around the world.
-
AdvaMed urges tailored tariff approach for medtech
CEO Scott Whitaker said the medtech lobbying group stands ready to work with President Donald Trump to address trade imbalances by confronting unfair foreign practices in the sector.
-
‘A deal is a deal’: EU halts US pact over Trump’s new global tariff
The bloc said it needed “full clarity” on the United States’ tariff plans after a Supreme Court ruling last week struck down many levies.
-
Guardant buys MetaSight for $59M upfront to acquire blood test tech
MetaSight uses metabolomics, lipidomics and proteomics mass spectrometry technologies to develop tests for specific diseases, including conditions outside of oncology.